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Abstract
Mood and substance use disorders (SUDs) are men-
tal conditions that are highly prevalent in the general
population. Cooccurrence of major depression and
SUD, also known as dual depression, is very common
in the field of substance addiction. Sex differences
are found in both major depression and SUD. This
review, after presenting the state of the art of dual
depression as regards prevalence, ethiopathologic
mechanisms, and clinical aspects, is focused on dual
depression in women. An overview of some potential
factors associated with the sex gap in dual depres-
sion such as injecting, sexual risk behavior, intimate
partner violence, and the reproductive cycle is pre-
sented.
Key Words: depression, dual pathology, comorbid-
ity, women, recommendations, substance use disor-
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Mood and substance use disorders(SUDs) are mental illnesses that
are highly prevalent in the general popu-
lation and are known to be among the
leading causes of the global disease bur-
den.1 Sex differences are found in both
major depression (MD) and SUD: a higher
incidence of depressive disorders has been
reported for women,2 whereas SUD are
more prevalent in men.3 The cooccur-
rence of MD and SUD, also denominated
dual depression, is very common4 and
worsens the prognosis of patients with a
poor response to the treatment of both
disorders.5,6 To date, there has been lim-
ited evidence concerning dual depression
among women. In this review, after
presenting the state of the art of dual
depression with respect to prevalence,
ethiopathologic mechanisms, and clinical
aspects, we will focus on this condition in
female individuals and some potential
factors involved in the sex gap observed.
DUAL DEPRESSION: AN
OVERVIEW
Epidemiological Data
The prevalence of dual depression
varies from 12% to 80%.7–9 Such a wide
range can be explained by a number of
factors, the most relevant being the
characteristics of the sample studied
(general population, patients seeking
treatment in addiction/mental health
facilities or elsewhere such as prisons,
homeless individuals); the main sub-
stance of use (alcohol, tobacco, cocaine,
opiates, sedatives, cannabis); the diag-
nostic criteria employed (Diagnostic
and Statistical Manual of Mental
Disorders-DSM or International Classi-
fication of Diseases-ICD in its different
versions); and the diagnostic tools used
(such as the Psychiatric Research Inter-
view for Substance and Mental Disor-
ders(PRISM), the Structured Clinical
Interview for DSM-SCID, Schedules for
Clinical Assessment in Neuropsychiatry-
SCAN, and screening interviews such as
the Dual Diagnosis Screening Instru-
ment-DDSI). In a systematic review
and meta-analysis of epidemiological
studies in the general population be-
tween 1990 and 2014, the strong asso-
ciation between depression and SUD
was confirmed.10 This association was
greater for illicit drugs [odds ratio, 3.80;
95% confidence interval (CI), 3.02-
4.78] than for alcohol (odds ratio,
2.42; 95% CI, 2.22-2.64) and was stron-
ger for disorders with dependence
disorder criteria than for abuse, irre-
spective of whether it was based on
lifetime prevalence or during the pre-
vious 12 months. As expected, in non-
substance users (wherein MD is more
frequent in female individuals)11 and in
SUD subjects, comorbid MD is twice as
common in women as in men. Interest-
ingly, in women diagnosed with SUD,
cooccurrent MD is more frequent than
in those without SUD; therefore, female
individuals with SUD are a particularly
vulnerable group for MD.12,13 Further-
more, in female illicit drug users, pri-
mary MD was more common (17%)
than substance-induced depression
(10%). Being a female individual and
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having a lifetime borderline personality
disorder doubles the risk of presenting
independent disorders.13
In a study of 162 patients with
alcohol addiction, the prevalence of
comorbid psychiatric disorders was
higher in women (82.5%) than in men
(63.9%), with comorbid MD being sig-
nificantly elevated among the former
(67.5% vs. 38.5%).14 In addition, it
was observed that although women
start drinking later than men, they take
less time to develop dependence symp-
toms and meet fewer severity criteria
than men. In a sample of 55 abstinent
cocaine-addicted participants with life-
time cocaine use disorders (15 women
and 40 men), women had an increased
prevalence of comorbid psychiatric dis-
orders, with 53.3% of them reporting
mood disorders in comparison with
32.5% in men.15
More specifically, women who in-
ject drugs (WWID) constitute a partic-
ularly vulnerable group. Injecting,
sexual risk behavior, prostitution, inti-
mate partner violence (IPV), blood-
borne virus infections, and psychiatric
disorders are experiences and adverse
health outcomes frequently found in
this population. A recent study included
a total of 226 female individuals who
had injected drugs in the past 6 months,
recruited in both treatment and harm
reduction facilities from 5 European
countries. The majority of participants
(87%) screened positive for at least 1
lifetime psychiatric disorder. The most
common conditions were depression
(76%), panic (54%), and posttraumatic
stress disorder (PTSD) (52%). WWID
and girls who inject drugs, who were
recruited from drug treatment facilities
were almost 3 times as likely (OR, 2.89;
95% CI, 1.30-6.43; P= 0.007) to meet
the criteria for a lifetime psychiatric
disorder than those recruited from
harm reduction ones. The principal dif-
ferences were found in dysthymia (OR,
5.32; 95% CI, 2.27-12.48; P= 0.000)
and PTSD (OR, 1.83; 95% CI, 1.02-
3.27; P= 0.040).16
Etiopathologic Mechanisms
The high concurrence of MD
and SUD can be explained mainly by
3 nonexcluding hypotheses: (a) SUD
and MD share the same common risk
factors, such as stressful life events,
psychological trauma, genetic vulner-
ability, and/or neurobiological altera-
tions leading to the appearance of
both disorders, without a causal rela-
tionship between them; (b) the contin-
ued use of certain substances leads to
neurobiological changes through neu-
roadaptative mechanisms that mediate
MD; and (c) SUD develops to relieve MD
(self-medication hypothesis).
In both disorders (MD and SUD),
genetic and environmental factors are
essential in facilitating neurobiolo-
gical mechanisms related to pathogen-
esis.17 The main molecular mechanisms
involved in the neurobiology of depres-
sion include those of the monoaminergic
system, the hypothalamic-pituitary-adre-
nal system, the immunologic system,
central nervous system neurotrophic
factors, the endocannabinoid system, cir-
cadian rhythms, food intake, the metabo-
lism system, and gut microbiota.18–22 The
majority of these also play a role in the
development of SUD17,20,23 and alcohol-
induced liver injury.24 Significantly, the
brain reward circuits, which are impli-
cated in the pathogenesis of addiction,
are additionally involved in the neuro-
biology of depressive disorders.25
Clinical Aspects
The diagnosis of MD in a current
drug-using patient is principally hin-
dered by the acute or chronic effects of
substance use (both chronic intoxica-
tion and withdrawal), which can mimic
depressive symptoms. According to the
DSM-5, in an SUD patient, a distinction
must be made between (i) a primary MD
disorder, (ii) expected effects of drug
intoxication/withdrawal, and (iii) an in-
duced MD disorder (Table 1).
It is important to note that, in the
case of SUD, because of cocaine, opiate,
or polydrugs, an MD episode usually
occurs frequently, irrespective of con-
sumption,13 whereas, in the case of
alcohol, a higher prevalence is de-
scribed in association with induced de-
pression.26 Both types of depression
(primary and induced) can be found in
the same patient.27
Furthermore, the coexistence of
SUD and MD has been associated with
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an unfavorable course of both diseases,
with worse response to treatment and
poorer prognosis.4,6 Thus, follow-up
studies in user patients have observed
that the presence of depressive
episodes, both primary and induced,
strongly facilitate consumption re-
lapse.28,29
Several studies have also observed
that SUD and MD comorbidity increases
clinical severity and the risk of suicidal
behavior.30,31 In addition, these pa-
tients are more likely to develop other
medical comorbidities, making treat-
ment even more difficult. As is expected
from their marked clinical severity,
such individuals also show considerably
poorer psychosocial function and make
greater use of health resources, includ-
ing emergency services and psychiatric
hospitalizations.5,29,32,33 Moreover, it
has been reported that patients with
MD are twice as likely to develop 1
SUD, just as those presenting an SUD
have twice the risk of suffering an MD
throughout their lives.34
DUAL DEPRESSION IN FEMALE
INDIVIDUALS
The higher prevalence of depres-
sion in female individuals than in male
individuals has been well established.11
A number of potential risk factors that
may explain the difference in estimated
MD prevalence between both genders
in the general population have been
recently reviewed by Kuehner. Table 2
summarizes the possible factors at 3
different levels: biological, psychologi-
cal, and environmental.35
Focusing on dual depression in
women, the present review has cen-
tered mainly on the association of dual
depression and injecting, sexual risk
behavior, IPV, and the reproductive
cycle.
Injecting and Sexual Risk Behavior
In contrast to men, female drug
users present greater psychopathology
and risk behavior, which increase the
probability of human immunodefi-
ciency virus (HIV) and hepatitis C virus
infection.36,37 Sharing needles and in-
jecting paraphernalia, reporting sexual
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TABLE 1. Primary, Induced, Expected Effects
Diagnoses Definition
Primary Mental disorders that are not
induced by substances or
arising from medical
illness,eg, independent
disorders
Substance
induced
Disorders that seem to be in
relation with substance use
or withdrawal but can be
considered excessive with
regard to the expected
effects
Expected
effects
This refers to symptoms
considered specific to
intoxication or withdrawal
from a given substance,
which should therefore not
be taken into account as
symptoms for diagnosing
depression (eg, insomnia
during acute stimulant
poisoning or during a
period of opiate
withdrawal)
TABLE 2. Potential Factors Involved in the Sex Gap in Depression Based on Kuehner35
Biological Factors Psychological Factors Environmental Factors
Genetic risk Neuroticism and negative
affect
Early adversity: childhood sexual
abuse
Gene-environment
interactions
Absence of positive affect Interpersonal violence after
childhood
Hormones Interpersonal orientation Common life events: exposure to
stress
Physiological stress
response
Rumination and
corumination
Common life events: susceptibility
to stress
Body shame and
dissatisfaction
Societal structural sex inequities
Farre´ et al
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risk behavior, exchanging sex for money
or drugs, and not using condoms are
considered risk behaviors that put wom-
en at greater danger of HIV/hepatitis C
virus transmission.38 The literature has
reported that depression among WWID
is associated with injection risk behav-
ior such as sharing needles.39 Evidence-
based psychosocial interventions have
described reductions in injecting/sexual
risk behavior and depressive symptoms
among female drug injectors37
IPV
Young women experience a great-
er number of interpersonal stressors
than men.40 Histories of psychiatric dis-
orders, IPV, and childhood abuse are
common in female substance users
under treatment. Research suggests that
such backgrounds result in poorer treat-
ment outcomes. The relationship of
IPV, childhood abuse, and psychiatric
disorders in 118 female drug users
under treatment in Barcelona was eval-
uated.41 The probability of experienc-
ing IPV was more than 2-fold greater
among those with any depressive disor-
der, and over 3 times greater for those
who reported attempting suicide, met
criteria for borderline personality disor-
der, or had been abused in childhood.
Experiencing violence is considered
one of the most important psychosocial
risk factors for psychiatric disorders in
women.42
Furthermore, IPV victims seeking
treatment for SUD are more likely to
experience drug-taking risk behavior,
which may be explained by the negative
influence/control of the perpetrator,43
thus increasing the danger of HIV/Hep-
atitis C.
Reproductive Cycle
The reproductive cycle is a crucial
phase in which many women may ex-
perience MD, including premenstrual
dysphoric disorder, partum and post-
partum depression, and menopausal
depression. Maternal depression is one
of the major contributors to pregnancy-
related morbidity and mortality. Perina-
tal depression in low-income and
middle-income countries is highly
prevalent, affecting about 1 in 4 women
antepartum and 1 in 5 postpartum. In a
recent review, the pooled prevalence
estimate of antepartum depression was
25.3% (95% CI, 21.4-29.6) across 51
studies and that of postpartum depres-
sion was 19.0% (95% CI, 15.5-23.0)
across 53 studies. Maternal depression
(antepartum and postpartum) has been
linked to negative health-related behav-
ior and adverse outcomes, including
psychological and developmental dis-
turbances in infants, children, and
adolescents.44
Alcohol and other drug use during
pregnancy is a major risk factor for
maternal morbidity and neonatal compli-
cations. Tobacco consumption is associ-
ated with spontaneous miscarriage, fetal
growth restriction, and preterm delivery.
Heavy caffeine use may be linked with
first-trimester loss. The misuse of alcohol
has a significantly potential impact on
pregnancy with fetal alcohol spectrum
disorder being the most severe. Opioids
and sedative hypnotics may not be
strongly associated with teratogenicity,
but fetal sedation and withdrawal at the
time of delivery is a consequence of their
long-term effects. Methadone, morphine,
and buprenorphine maintenance are
suggested for opiate-addicted pregnant
patients.
Approximately half of the patients
suffering from an SUD or alcohol-related
disorder also match the criteria for some
other psychiatric condition, although little
is known about comorbidity among
substance-misusing pregnant women. In
a sample of 49 pregnant women with SUD
in Finland, 57% of the substance-
misusing ones had psychiatric illnesses.
In the comorbid group, depression
(43%) and anxiety disorders (36%) were
the most common diagnoses.45 In a
prospective study of a cohort of 4447
substance-using mothers (pregnant or pa-
renting) who were enrolled during 2000
to 2002 in drug-abuse treatment pro-
grams, the participants had 8.4 times
greater mortality than that observed
among women of a similar age who were
not substance abusers. Drug overdose
(28.8%), cardiovascular disease (10%),
and alcohol or drug disorders (8.9%)
were the leading causes of death. Greater
difficulties with employment, medical is-
sues/health, and psychiatric problems
contributed to the elevated mortality.
The deceased women were found to have
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had a greater number of psychiatric symp-
toms (eg, depression, anxiety, and hallu-
cinations) and to have received more
prior inpatient psychiatric treatment.46
In the United States, in a sample of
502 female adolescents and adults with
SUD who reported having been preg-
nant in the previous year, the preva-
lence of coocurring mental disorders
was 91.3%.47
Postpartum mood disorders affect
B10% to 20% of women and have ad-
verse consequences for both mother and
baby. However, lifetime substance use has
received limited attention in relation to
this issue. Prevat et al studied the associ-
ations of lifetime alcohol and drug use
with postpartum mental health problems
among 100 women for B3 months.48
Their findings suggest that lifetime sub-
stance use increased the variability ex-
plained in postpartum PTSD (P= 0.011)
above and beyond sociodemographic
characteristics and mental health history.
Lifetime drug use was specifically associ-
ated with postpartum stress (P= 0.021)
and anxiety (P= 0.041), whereas life-
time alcohol use was not (PsZ0.128).
The results suggest that lifetime drug use
is associated with postpartum mood
disorders.48
CONCLUSIONS
Dual depression is more prevalent
in women than in men and more fre-
quent than expected in women without
any SUD. A number of risk factors may
help to explain the sex differences. Wom-
en with SUD report a high occurrence of
injecting and sexual risk behavior, pros-
titution, and IPV, which are experiences
associated with dual depression.
Because of the dual diagnoses,
patients present greater medical se-
verity (higher risk to be HIV and HCV
infected), worse social functioning, and
poorer response to treatment and prog-
nosis. The treatment of dual depression
should take into account the prevalence
of these risk factors in female drug users
in order to develop the most appropri-
ate approach (Table 3).
Research and practice should con-
sider all these risk factors in order to
improve diagnosis and have more
effective treatment options for these
patients. In addition, biological factors in
dual depression should receive greater
attention in order to obtain firm conclu-
sions regarding their influence. More
longitudinal studies are required to estab-
lish the directionality of the factors affect-
ing MD and SUD in women.
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